Impact of p16 Status on the Efficacy of Pembrolizumab Combined Nimotuzumab in Recurrent/Unresectable/Metastatic Head and Neck Squamous Cell Carcinoma Patients

Key Points

• The research aims to investigate how p16 status impacts the effectiveness of Pembrolizumab and Nimotuzumab in treating recurrent, unresectable, or metastatic head and neck squamous cell carcinoma.
• Evaluated the efficacy of Pembrolizumab combined with Nimotuzumab in HNSCC patients.
• Assessed differential p16 expression in the participant population.
• Monitored overall response rate (ORR) and overall survival (OS) metrics.
• The combination therapy improved overall response rate (ORR) and overall survival (OS).
• Differential p16 expression influenced the treatment's effectiveness.
• The therapy maintained a reliable safety profile.